Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThRiL for Previously Treated Waldenstrom Macroglobulinemia
NCT01779167Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Jun 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide, lenalidomide in Waldenstrom macroglobulinemia (WM), sponsored by Weill Cornell Medicine. Started Jun 2012; status: terminated.
02
Drugs
thalidomidelenalidomide
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT01779167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01779167.